1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Betahistine Leads A Raft Of UK Rises In August

Pricewatch UK – August 2023

 
• By Dave Wallace

With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.

Price Watch UK
• Source: Alamy

Amid treble-digit-percentage price rises for several different generic molecules in the UK in August, betahistine tablets saw the steepest increase, according to the latest figures from market researcher WaveData.

Based on trade prices to UK independent pharmacists, WaveData calculated that 16mg betahistine tablets in 84-count packs experienced an average price rise of 342% to £6.27 ($7.70), as the cheapest price on offer jumped by more than half to £0.95

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

More from Market Intelligence

Vardenafil Leads UK Rises In January

 
• By Dave Wallace

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.

UK Gabapentin Prices Shoot Up In December

 
• By Dave Wallace

UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.

UK Memantine Prices Spike In November

 
• By Dave Wallace

Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.